Generic placeholder image

Current HIV Research


ISSN (Print): 1570-162X
ISSN (Online): 1873-4251

Sildenafil Plasma Concentrations in Two HIV Patients with Pulmonary Hypertension Treated with Ritonavir-Boosted Protease Inhibitors

Author(s): Pierangelo Chinello, Stefania Cicalini, Simona Pichini, Roberta Pacifici, Massimo Tempestilli and Nicola Petrosillo

Volume 10 , Issue 2 , 2012

Page: [162 - 164] Pages: 3

DOI: 10.2174/157016212799937263

Price: $58


Sildenafil is increasingly used for the therapy of pulmonary arterial hypertension (PAH) in HIV infected patients. However, concerns exist about pharmacokinetic interactions between sildenafil and protease inhibitors (PI); in particular, ritonavir has been shown to increase sildenafil AUC and Cmax by several folds. The aim of our study was to determine the plasma levels of sildenafil and PI in two HIV patients with PAH treated with antiretroviral therapy including ritonavir-boosted PI. Our patients both experienced sildenafil Cmax above 500 ng/mL; however, they did not report any significant adverse reactions to sildenafil during the follow-up period. Therapeutic drug monitoring of sildenafil should be taken in consideration during treatment in order to avoid overdosage.

Keywords: HIV, protease inhibitors, pulmonary arterial hypertension, sildenafil

Rights & Permissions Print Export Cite as
Related Journals
Related eBooks
Article Metrics
Related Articles
© 2020 Bentham Science Publishers